Biodesix

Precision Medicine And AI Will Fuel Diagnostic Evolution

AnalystHighTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

11 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$2.00

77.3% undervalued

21 Aug

US$0.45

-75.0%

14.4%

Author's Valuation

US$2.0

77.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$2.0

77.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

16.21%

Healthcare Services revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.39%

Calculation

US$7.09m

Earnings '28

52.54x

PE Ratio '28

US$372.27m

Market Cap '28

US$372.27m

Market Cap '28

150.19m

No. shares '28

US$2.48

Share Price '28

US$2.48 Share Price '28

Discounted to 2025 @ 7.46% p.a.

US$2.00

Fair Value '25